AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01427387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0456
Description: oral
Study NCT01427387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01214447 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study - no intervention
Study NCT01420640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 24 weeks of supervised aerobic exercise training, 2x/week
Study NCT01597349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP01
Description: Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
Study NCT01907048 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
Study NCT01907048 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Survey to measure patient awareness and understanding of the key messages in the patient card.
Study NCT04174053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enteric capsule
Description: Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
Study NCT05157750 — intervention group
Intervention type: OTHER
Intervention: Recording of major clinical events
Description: During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
Study NCT03134053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock-wave
Description: to treat painful and retracting scars
Study NCT03739879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Trainer Philips Respironics
Description: Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
Study NCT02819479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% Mannitol
Description: Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.
Study NCT02819479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Intra-arterial Bevacizumab
Description: Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery.
Study NCT03761914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: Adjuvant
Study NCT00231179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting professional support model
Description: Home visits and telephone calls keyed to well child visits.
Study NCT00231179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
Study NCT01115946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT05727995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO7
Description: The use of PICO is contraindicated in the presence of:~* Patients with malignancy in the wound bed or margins of the wound~* Previously confirmed and untreated osteomyelitis~* Nonenteric and unexplored fistulas~* Necrotic tissue with eschar present~* Exposed arteries, veins, nerves or organs~* Exposed anastomotic sites~* Emergency airway aspiration~* Pleural, mediastinal or chest tube drainage~* Surgical suction.
Study NCT05727995 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual care dressing
Description: usual care dressing
Study NCT00699543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroflex Please stent implantation
Description: Use Coroflex Please stent in the treatment of coronary stenosis
Study NCT00699543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus stent implantation
Description: Use Taxus stent in the treatment of coronary stenosis
Study NCT01115946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril
Description: oral
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLTA3698A
Description: Subcutaneous repeating dose
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Subcutaneous repeating dose
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Stable dose if not on methotrexate
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: Stable dose if not on methotrexate
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leflunomide
Description: Stable dose if not on methotrexate
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Stable dose if not on leflunomide
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Stable dose if not on leflunomide
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Stable dose if not on leflunomide
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT01225393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT02703805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit For Function Program
Description: A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
Study NCT02703805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard YMCA membership
Description: A 12 week standard YMCA membership.
Study NCT00829166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Study NCT00829166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Study NCT00829166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Study NCT05563532 — intervention group
Intervention type: BEHAVIORAL
Intervention: dental anxiety and oral hygiene
Description: Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
Study NCT01997567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
Study NCT01997567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
Study NCT00596518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200
Description: The drug is administered as a single dose of four 5-mg tablets
Study NCT02352246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical activity programs steady-state exercise (SSE) program
Description: The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
Study NCT02352246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical activity programs high intensity intermittent exercise (HIIE)
Study NCT00718861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00718861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT01401829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 150 weekly minutes walking
Description: 12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
Study NCT01401829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 75 weekly minutes walking
Description: 12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
Study NCT01401829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/Flexibility exercise
Description: 12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
Study NCT03318107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal probe using photoacoustic and ultrasound imaging
Description: -Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
Study NCT03761914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Participants receive 70 μg GM-CSF SC on Day -2 and on Day 1 before each GPS injection. The GM-CSF injections occur at the same anatomical site of the next planned study treatment injection.
Study NCT01048229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg rasagiline once daily (plus placebo twice daily)
Study NCT01048229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
Study NCT03312140 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Choline Chloride
Study NCT03505697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
Study NCT03505697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band
Study NCT00614341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedRelief SE 55
Description: 4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
Study NCT04570280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercises
Description: Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
Study NCT04570280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Exercises
Description: Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
Study NCT04570280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Range of Motion Exercises
Description: Range of Motion Exercises will be applied 3 times a week for 12 weeks.
Study NCT04570280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of Motion Exercises
Description: Range of Motion Exercises will be applied 3 times a week for 12 weeks.
Study NCT03521609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional intelligence intervention
Description: Brief group intervention based on emotional intelligence
Study NCT01005472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT01005472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00365976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone 3 mg po nightly for duration of study blind phase.
Study NCT00365976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nightly over duration of double blind study phase
Study NCT04069910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04069910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04069910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04069910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04069910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS/SRT
Study NCT04069910 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS/SRT
Study NCT04069910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT04069910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT00985192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT00985192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00114959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m\^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule.
Study NCT00114959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
Study NCT01120574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home mechanical ventilation
Description: Home mechanical ventilation will be performed with a bilevel pressure ventilator.
Study NCT03121352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4.5 IV day 1 of 21-day cycle
Study NCT03121352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 75mg/m2 IV days 1, 8 and 15 of 21-day cycle
Study NCT03121352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 21 days
Study NCT00461266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid
Study NCT00461266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Description: As prescribed
Study NCT00461266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy
Description: As prescribed
Study NCT02333240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management of postnatal anti-hypertensive treatment
Description: Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
Study NCT01889810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 supplementation
Description: 3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
Study NCT01238575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered for up to 8 weeks.
Study NCT01238575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
Study NCT01889810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplementation
Description: 3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
Study NCT02128503 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HBV DNA level monitoring
Description: HBV DNV level being monitoring regularly
Study NCT02394886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Study NCT03855306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibesyn
Description: 1 tablet contains 5 mg Glibenclamide
Study NCT03855306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daonil
Description: 1 tablet contains 5 mg Glibenclamide
Study NCT01534715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN529
Study NCT03336398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride in saline
Description: 0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
Study NCT00593554 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation
Description: 8 Gy on Day -9
Study NCT03336398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline will be administered with the other MRS scan
Study NCT01082913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SSE
Description: Use of SSE or not use of SSE
Study NCT01543451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsiglutide
Description: 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Study NCT01543451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy